Recursion Pharmaceuticals announced that it has won two Fierce Innovation awards from the biotech and pharmaceutical industries today for its innovative platform. The awards, “Best Biotech Innovation” and “Best In Show—New Product or Service,” recognize Recursion’s disruptive combination of experimental biology and artificial intelligence applied to drug discovery.

 “We are pleased to be recognized as industry-leading innovators by our distinguished peers,” said Chris Gibson, co-founder and CEO of Recursion. “Our platform represents a different approach to drug discovery—a true merging of biology and technology.”

“Traditional drug discovery can take more than a decade and billions of dollars per approved compound,” Gibson continued. “Recursion’s platform can radically increase the scale at which drugs are discovered, saving years of development time and the associated costs.”

The Fierce Innovation Awards: Life Sciences Edition is an awards program from the publisher of FierceBiotech and FiercePharma. Recursion’s computationally intelligent platform was recognized for its ability to span the life science industry, from drug screening to target identification to compound intelligence.

“Because we model diseases and conditions in human cells, our platform can be deployed across nearly any aspect of human cellular biology,” said Gibson. “Drug discovery is the first and most advanced of Recursion’s real-world applications.”

In less than a year, Recursion has screened hundreds of disease models and identified more than twelve compounds across seven disease states that show sufficient potential to advance to preclinical development.

Fierce Innovation award applications are reviewed by an exclusive panel of executives from Medidata, PwC, Verily, Otsuka Pharmaceuticals, Amgen and more.

Judges based their decision on effectiveness, technical innovation, competitive advantage, financial impact and true innovation. Recursion’s platform was selected from among five finalists in Biotech Innovation by championing innovation in the face of great competition, with forward thinking and the greatest potential to have the biggest impact on the industry. Recursion was a finalist alongside such outstanding innovators as Bicycle Therapeutics, Humacyte, Covance, LexisNexis, The Michael J Fox Foundation and Bayer AG + Facebook.